Suraksha Diagnostic Limited Sets November 10 Q2 FY27 Board Meeting

Suraksha Diagnostic Limited is scheduled to consider its Q2 FY27 results on November 10, 2026, following a ₹12.85 crore consolidated profit for Q1 FY27, up 40% year on year. The board meeting will approve unaudited financial results for the quarter and half-year ended September 30, 2026.

When will Suraksha Diagnostic announce Q2 FY27 results?

Suraksha Diagnostic Limited has scheduled a board meeting on Tuesday, November 10, 2026, to consider and approve its unaudited financial results for Q2 FY27 and the first half of FY27. The reporting period covers July to September 2026, while the half-year period ended on September 30, 2026.

The company informed the NSE about the proposed meeting on November 5. The filing also said the trading window for designated persons would reopen after 48 hours from the public disclosure of the financial results. This is the standard process used to manage trading by insiders around price-sensitive announcements.

The available corporate-action information described the Q2 results as pending at the time of the notice. Therefore, no September-quarter revenue, profit, margin, or operating metrics were included in the announcement. Investors will need to rely on the board-approved results and accompanying disclosures once they are released.

Suraksha Diagnostic is among 44 companies scheduled to announce Q2 FY27 earnings on November 10. The wider results calendar also includes companies from jewellery, tyres, shipbuilding, rail equipment and seafood sectors, placing the company's update within an active day for Indian equity-market earnings disclosures.

What will management discuss after the results announcement?

Suraksha Diagnostic will hold a virtual analyst and investor conference call on November 13, 2026, at 11:00 AM IST to discuss its Q2 and H1 FY27 financial results. The company announced the call on November 6 and said the discussion would cover the unaudited results for the quarter ended September 30.

Shareholders and other market participants can use the call to hear management's discussion of the reported performance and outlook. The company said details would be posted on its website. It also specified that no unpublished price-sensitive information would be shared during the call.

The filing noted that the schedule may change because of operational exigencies. The November 13 call follows the board meeting by three days, giving investors an opportunity to assess both the statutory financial statement and management's explanation of operating developments during the half-year.

What did Suraksha Diagnostic report in the previous quarter?

Suraksha Diagnostic reported a consolidated profit attributable to owners of ₹12.85 crore for the quarter ended June 30, 2026, compared with ₹9.20 crore a year earlier. The reported year-on-year increase was 40%, while the company also recorded consolidated total comprehensive income attributable to owners of ₹12.99 crore.

Consolidated total income for Q1 FY27 was ₹88.73 crore, based on the financial figures disclosed in lakhs and converted to crore. Standalone total income was ₹45.65 crore, while standalone profit stood at ₹12.58 crore. The source material also described last-quarter sales growth at 20.7% year on year.

The company also disclosed that its subsidiaries contributed ₹44.29 crore in revenue in Q1 FY27 but recorded a combined net loss after tax of ₹1.18 crore. These subsidiary figures are relevant because the September-quarter consolidated result will show whether group operations continue to differ from the standalone business.

Which operating and governance matters should investors track?

Investors should track any update on Suraksha Diagnostic's exposure related to its dispute with the Government of Meghalaya. As of June 30, 2026, the company reported exposure of ₹3.94 crore under assessment and had made a provision of ₹0.31 crore. The company had linked the dispute to operational losses in its earlier disclosure.

The September-quarter result may provide additional information only if the company chooses to disclose a fresh assessment, provision, or operating impact. The current board-meeting notice does not provide a new update on the matter, so any change should be evaluated against the approved Q2 financial statement and notes to accounts.

Suraksha Diagnostic also appointed Dinesh Gupta as Chief Financial Officer and Group CFO, effective August 24, 2026. The appointment came after the June-quarter results. Governance changes can be relevant for investors where they coincide with group-level reporting, financial controls, or discussion of subsidiary performance, although the filings provided do not draw any direct link between the appointment and operating outcomes.

How could the Q2 result matter for Suraksha Diagnostic shareholders?

The Q2 FY27 release will matter because it will show whether the 20.7% sales growth and 40% year-on-year profit growth reported in the June quarter were sustained through the September quarter. Until the board-approved filing is published, there is no disclosed basis to assess the company's second-quarter revenue, profitability, or margin movement.

For shareholders, the November 10 result and November 13 management call are the next formal events for evaluating the company's half-year financial performance. Attention is likely to focus on consolidated income, profit attributable to owners, subsidiary losses, and disclosures connected with the Meghalaya matter. These items have been specifically identified in the company's earlier financial information and corporate announcements.

Conclusion

Suraksha Diagnostic's immediate corporate event is the November 10 board meeting to approve Q2 and H1 FY27 unaudited results. The latest available quarter showed ₹88.73 crore of consolidated total income and ₹12.85 crore of profit attributable to owners, but these June-quarter figures do not indicate the yet-to-be-filed September-quarter outcome.

The next confirmed milestone is the virtual analyst and investor call at 11:00 AM IST on November 13, 2026. Investors should watch for the final Q2 financial statement, any change in subsidiary performance, and any further disclosure on the Government of Meghalaya dispute and associated provision.